Journal: Oncotarget

Article Title: Circadian factors BMAL1 and RORα control HIF-1α transcriptional activity in nucleus pulposus cells: implications in maintenance of intervertebral disc health

doi: 10.18632/oncotarget.8521

Figure Lengend Snippet: A . Immunohistochemical localization of BMAL1 in rat intervertebral disc. Sagittal sections of the mature rat intervertebral disc, immunostained with BMAL1 antibody, showed prominent nuclear expression in NP tissue. B . Western blot analysis of BMAL1 and RORα expression in NP tissues isolated from three rats showed positive expression for both the proteins. C . qRT-PCR analysis of BMAL-1 and RORα mRNA expression from NP and AF tissues from rat discs (n=3 animals/group) D . qRT-PCR analysis of BMAL1, RORα, ARNT, ARNT2, ARNTL2 and CLOCK expression in rat NP cells cultured under hypoxia (1% O 2 ). None of the genes showed significant increase in hypoxia. E . Western blot analysis of BMAL1 and RORα in NP cells cultured under hypoxia. F ., G . Densitometric analysis of multiple blots shown in (E) above. No significant differences were seen between normoxic and hypoxic levels of BMAL1 and RORα. Data is represented as mean ± SE, n=3, p<0.05.

Article Snippet: Antibodies used were anti-BMAL1 (#14020, Cell Signaling), anti-CLOCK (#5157, Cell Signaling; #3517, Abcam), anti-RORα (#NBP1-52813, Novus), anti-HIF-1α (#MAB1536, R&D Systems; #ab2185, Abcam), anti-HIF-1β/ARNT (#5537, Cell Signaling), anti-GAPDH (#NB300-221SS, Novus) and anti-Lamin A/C (#2032, Cell Signaling).

Techniques: Immunohistochemical staining, Expressing, Western Blot, Isolation, Quantitative RT-PCR, Cell Culture

Journal: Oncotarget

Article Title: Circadian factors BMAL1 and RORα control HIF-1α transcriptional activity in nucleus pulposus cells: implications in maintenance of intervertebral disc health

doi: 10.18632/oncotarget.8521

Figure Lengend Snippet: A . Evaluation of BMAL1 and RORα expression by Western blot in NP cells stably transduced with lentivirus expressing BMAL1 shRNA. B ., C . Densitometric analysis of multiple blots shown in (A) demonstrated decreased BMAL1 (B) and RORα (C) expression in BMAL1-silenced cells under both normoxia and hypoxia. D . HRE activity of BMAL1-silenced NP cells is significantly lower than cells transduced with control shRNA. E .- G . Evaluation of BMAL1 control of HIF-α-TAD function. BMAL1 overexpression had no effects on HIF-1α-C-TAD (E), HIF-1α-N-TAD (F), as well as HIF-2α-TAD (G) regardless of oxygen tension. Data is represented as mean ± SE, n= 3, * p<0.05.

Article Snippet: Antibodies used were anti-BMAL1 (#14020, Cell Signaling), anti-CLOCK (#5157, Cell Signaling; #3517, Abcam), anti-RORα (#NBP1-52813, Novus), anti-HIF-1α (#MAB1536, R&D Systems; #ab2185, Abcam), anti-HIF-1β/ARNT (#5537, Cell Signaling), anti-GAPDH (#NB300-221SS, Novus) and anti-Lamin A/C (#2032, Cell Signaling).

Techniques: Expressing, Western Blot, Stable Transfection, Transduction, shRNA, Activity Assay, Over Expression

Journal: Oncotarget

Article Title: Circadian factors BMAL1 and RORα control HIF-1α transcriptional activity in nucleus pulposus cells: implications in maintenance of intervertebral disc health

doi: 10.18632/oncotarget.8521

Figure Lengend Snippet: A. , B . Evaluation of HRE activity in NP cells transfected with 50-150 ng of RORα with or without 25 ng of HIF-1α, after 24 h hypoxia and normoxia treatment. Under normoxia, compared to HIF-1α alone, cells co-transfected with RORα and HIF-1α showed a significant increase in HRE activity at all doses, while under hypoxia this increase was seen at 150 ng of RORα. C ., D . Treatment of NP cells with increasing dose of highly specific, small molecular RORα inhibitor, ML176 (2-10 μM), resulted in decrease in activity of endogenous HIF protein under both normoxia (C) and hypoxia (D). E .- G . Regulation of HIF-α-TAD function by RORα in NP cells. Treatment with ML176 (10 μM) under both normoxia and hypoxia resulted in decrease in HIF-1α-C-TAD (E), HIF-1α-N-TAD (F) as well as HIF-2α-TAD (G) activities. Data is represented as mean ± SE, n=3, *p<0.05.

Article Snippet: Antibodies used were anti-BMAL1 (#14020, Cell Signaling), anti-CLOCK (#5157, Cell Signaling; #3517, Abcam), anti-RORα (#NBP1-52813, Novus), anti-HIF-1α (#MAB1536, R&D Systems; #ab2185, Abcam), anti-HIF-1β/ARNT (#5537, Cell Signaling), anti-GAPDH (#NB300-221SS, Novus) and anti-Lamin A/C (#2032, Cell Signaling).

Techniques: Activity Assay, Transfection

Journal: Oncotarget

Article Title: Circadian factors BMAL1 and RORα control HIF-1α transcriptional activity in nucleus pulposus cells: implications in maintenance of intervertebral disc health

doi: 10.18632/oncotarget.8521

Figure Lengend Snippet: A . Immunoprecipitation (IP) of BMAL1 and CLOCK from NP cells cultured under normoxia or hypoxia for 24 h followed by Western blot analysis using anti-HIF-1α, anti-BMAL1 and anti-CLOCK antibodies. BMAL1 bound to CLOCK, but neither BMAL1 nor CLOCK bound to HIF-1α irrespective of oxygen tension. Preimmune rabbit IgG was used as a negative control for IP assays. B . Pulldown of HIF-1α did not show co-precipitation of BMAL1, CLOCK, or RORα. HC: heavy chain of IgG, nsp: non-specific ( C ) Pulldown of HIF-1α showed co- precipitation of HIF-1β/ARNT, association was higher under hypoxia. D ., E . Treatment of NP cells with RORα inhibitor, ML-176 (10 μM), showed no effect on nuclear levels of HIF-1α. Densitometric analysis shown in (E) was performed on blots from 3 independent experiments, Data is represented as mean ± SE, * p < 0.05.

Article Snippet: Antibodies used were anti-BMAL1 (#14020, Cell Signaling), anti-CLOCK (#5157, Cell Signaling; #3517, Abcam), anti-RORα (#NBP1-52813, Novus), anti-HIF-1α (#MAB1536, R&D Systems; #ab2185, Abcam), anti-HIF-1β/ARNT (#5537, Cell Signaling), anti-GAPDH (#NB300-221SS, Novus) and anti-Lamin A/C (#2032, Cell Signaling).

Techniques: Immunoprecipitation, Cell Culture, Western Blot, Negative Control

Journal: Oncotarget

Article Title: Circadian factors BMAL1 and RORα control HIF-1α transcriptional activity in nucleus pulposus cells: implications in maintenance of intervertebral disc health

doi: 10.18632/oncotarget.8521

Figure Lengend Snippet: A .- B . qRT-PCR analysis of mRNA expression of select HIF-1 target genes following stable silencing of BMAL1 (A) or pharmacological inhibition of RORα activity by ML176 (10 μM) treatment. Knockdown of BMAL1 resulted in significant decrease in VEGF-A, enolase 1 (Eno1), PFKFB3 as well as RORα under both normoxia and hypoxia. B. NP cells treated with RORα inhibitor showed decreased mRNA expression of BMAL1, VEGF, PFKFB3 and Eno1. Expression of PHD2, another known HIF-1 target gene, remained unaffected in BMAL1 silenced and ML176 treated NP cells. Data is represented as mean ± SE. n=5, *p<0.1.

Article Snippet: Antibodies used were anti-BMAL1 (#14020, Cell Signaling), anti-CLOCK (#5157, Cell Signaling; #3517, Abcam), anti-RORα (#NBP1-52813, Novus), anti-HIF-1α (#MAB1536, R&D Systems; #ab2185, Abcam), anti-HIF-1β/ARNT (#5537, Cell Signaling), anti-GAPDH (#NB300-221SS, Novus) and anti-Lamin A/C (#2032, Cell Signaling).

Techniques: Quantitative RT-PCR, Expressing, Inhibition, Activity Assay

Journal: Frontiers in Cell and Developmental Biology

Article Title: Roles of Melatonin in Goat Hair Follicle Stem Cell Proliferation and Pluripotency Through Regulating the Wnt Signaling Pathway

doi: 10.3389/fcell.2021.686805

Figure Lengend Snippet: List of antibodies used for Immunofluorescence analysis and western blot.

Article Snippet: RAR related orphan receptor alpha , Anti-RORA rabbit ployclonal antibody , Sangon Biotech , D162141.

Techniques: Immunofluorescence, Western Blot, Binding Assay, Recombinant

Journal: Journal of Translational Medicine

Article Title: DNMT1-driven methylation of RORA facilitates esophageal squamous cell carcinoma progression under hypoxia through SLC2A3

doi: 10.1186/s12967-024-05960-8

Figure Lengend Snippet: Association analysis of RORA expression and ESCC diagnosis and prognosis. ( A ) Data of RNA-seq in ESCC tumor specimens and matched healthy esophageal samples were retrieved from UCSC XENA. R package ggplot2 showing the under-expression of RORA in ESCC tumor specimens versus normal tissues. ( B ) IHC assay was implemented to measure the expression of RORA in five pairs of ESCC tumor tissues and adjacent normal tissues. ( C ) ROC curve and AUC value analyzed by pROC package in R demonstrating the diagnostic potential for RORA. ( D and E ) Survival package in R indicating the correlation of RORA expression with overall survival of ESCC. *** P < 0.001

Article Snippet: For analysis of protein expression, we used primary antibodies from Proteintech (Wuhan, China) including rabbit anti-RORA polyclonal antibody (pA) (1:1,500, #10616-1-AP), rabbit anti-HIF1A polyclonal antibody (pA) (1:8,000, #20960-1-AP), rabbit anti-Snail pA (1:800, #13099-1-AP), rabbit anti-N-cadherin pA (anti-N-cad, 1:5,000, #22018-1-AP), rabbit anti-E-cadherin pA (anti-E-cad, 1:30,000, #20874-1-AP), rabbit anti-SLC2A3 pA (1:4000, #20403-1-AP), and mouse anti-β-actin monoclonal antibody (mAb) (1:10,000, #81115-1-RR).

Techniques: Expressing, Biomarker Discovery, RNA Sequencing, Diagnostic Assay

Journal: Journal of Translational Medicine

Article Title: DNMT1-driven methylation of RORA facilitates esophageal squamous cell carcinoma progression under hypoxia through SLC2A3

doi: 10.1186/s12967-024-05960-8

Figure Lengend Snippet: Inhibitory activity of RORA in ESCC cell viability and motility under hypoxia. ( A and B ) RT-qPCR and western blotting demonstrating that RORA expression increased in cells exposed to hypoxia. ( C ) The regulatory effect of HIF1A on RORA protein expression under hypoxia or normoxia was analyzed by western blotting. ( D ) The transfection efficiencies of shRORA and RORA ectopic expression plasmid in ESCC cells under hypoxia or normoxia were assessed by western blotting assay. ( E ) Under hypoxic conditions, CCK-8 assay revealing that RORA knockdown (KD) promoted cell viability, and RORA overexpression (OE) decreased cell viability. * P < 0.05, *** P < 0.001

Article Snippet: For analysis of protein expression, we used primary antibodies from Proteintech (Wuhan, China) including rabbit anti-RORA polyclonal antibody (pA) (1:1,500, #10616-1-AP), rabbit anti-HIF1A polyclonal antibody (pA) (1:8,000, #20960-1-AP), rabbit anti-Snail pA (1:800, #13099-1-AP), rabbit anti-N-cadherin pA (anti-N-cad, 1:5,000, #22018-1-AP), rabbit anti-E-cadherin pA (anti-E-cad, 1:30,000, #20874-1-AP), rabbit anti-SLC2A3 pA (1:4000, #20403-1-AP), and mouse anti-β-actin monoclonal antibody (mAb) (1:10,000, #81115-1-RR).

Techniques: Activity Assay, Quantitative RT-PCR, Western Blot, Expressing, Transfection, Plasmid Preparation, CCK-8 Assay, Knockdown, Over Expression

Journal: Journal of Translational Medicine

Article Title: DNMT1-driven methylation of RORA facilitates esophageal squamous cell carcinoma progression under hypoxia through SLC2A3

doi: 10.1186/s12967-024-05960-8

Figure Lengend Snippet: Suppressive function of RORA in ESCC cell migration and invasion under hypoxia. ( A ) Under hypoxic conditions, wound-healing assay showing that RORA KD enhanced cell motility, and RORA OE hindered migration. ( B ) Under hypoxic conditions, transwell assay demonstrating that cell invasiveness was facilitated by RORA KD and repressed by RORA OE. ( C and D ) IF microscopy revealing that RORA KD increased the levels of MMP2 and MMP9, which the two factors were downregulated following RORA OE. ( E ) Western blotting demonstrating the expression alteration of E-cad, N-cad and Snail following RORA KD and RORA OE. * P < 0.05, ** P < 0.01, *** P < 0.001

Article Snippet: For analysis of protein expression, we used primary antibodies from Proteintech (Wuhan, China) including rabbit anti-RORA polyclonal antibody (pA) (1:1,500, #10616-1-AP), rabbit anti-HIF1A polyclonal antibody (pA) (1:8,000, #20960-1-AP), rabbit anti-Snail pA (1:800, #13099-1-AP), rabbit anti-N-cadherin pA (anti-N-cad, 1:5,000, #22018-1-AP), rabbit anti-E-cadherin pA (anti-E-cad, 1:30,000, #20874-1-AP), rabbit anti-SLC2A3 pA (1:4000, #20403-1-AP), and mouse anti-β-actin monoclonal antibody (mAb) (1:10,000, #81115-1-RR).

Techniques: Migration, Wound Healing Assay, Transwell Assay, Microscopy, Western Blot, Expressing

Journal: Journal of Translational Medicine

Article Title: DNMT1-driven methylation of RORA facilitates esophageal squamous cell carcinoma progression under hypoxia through SLC2A3

doi: 10.1186/s12967-024-05960-8

Figure Lengend Snippet: Suppression of RORA in KYSE150 xenograft growth. ( A and B ) Images of mice and xenografts showing the inhibitory role of RORA in KYSE150 xenograft growth. ( C and D ) Reduced tumor volume and weight after RORA OE indicating the repression of RORA in KYSE150 xenograft growth. ( E ) RT-qPCR indicating the upregulation of RORA in lenti-RORA-transduced xenograft tumors. ( F ) Western blotting was employed to detect the expression of HIF1A, a biomarker of hypoxia, in the two groups of xenograft tumors. ( G ) IHC revealing that RORA OE reduced the ratio of the Ki-67-positive cells in KYSE150 xenograft tumors. ( H ) IF microscopy indicating that RORA OE repressed the growth of xenografts as measured by the reduced ratio of the PCNA-positive cells. ( I and J ) IF microscopy showing that RORA OE downregulated the levels of MMP2 and MMP9 in KYSE150 xenografts. * P < 0.05, ** P < 0.01, *** P < 0.001, ns: no statistically significant difference

Article Snippet: For analysis of protein expression, we used primary antibodies from Proteintech (Wuhan, China) including rabbit anti-RORA polyclonal antibody (pA) (1:1,500, #10616-1-AP), rabbit anti-HIF1A polyclonal antibody (pA) (1:8,000, #20960-1-AP), rabbit anti-Snail pA (1:800, #13099-1-AP), rabbit anti-N-cadherin pA (anti-N-cad, 1:5,000, #22018-1-AP), rabbit anti-E-cadherin pA (anti-E-cad, 1:30,000, #20874-1-AP), rabbit anti-SLC2A3 pA (1:4000, #20403-1-AP), and mouse anti-β-actin monoclonal antibody (mAb) (1:10,000, #81115-1-RR).

Techniques: Quantitative RT-PCR, Western Blot, Expressing, Biomarker Discovery, Microscopy

Journal: Journal of Translational Medicine

Article Title: DNMT1-driven methylation of RORA facilitates esophageal squamous cell carcinoma progression under hypoxia through SLC2A3

doi: 10.1186/s12967-024-05960-8

Figure Lengend Snippet: DNMT1 induces methylation of RORA in hypoxia-induced ESCC cells. ( A ) GSEA analysis revealing the association between RORA and DNA methylation. ( B ) TCGA samples from Ualcan database showing the augmentation of the promoter methylation level of RORA in esophagus cancer (ESCA). ( C and D ) TCGA samples from Ualcan database revealing the correlation of RORA’s promoter methylation level and tumor lymphatic metastasis (N) and pathological grade. ( E ) Schematic showing the four biotin-labelled RORA promoter probes and five fragments divided by the four probes. ( F ) Venn diagram revealing the 69 specific bound proteins in the F1 fragment and 97 specific bound proteins in the F2 fragment. ( G ) Venn diagram revealing the 20 specific bound proteins in the F3 fragment. ( H ) Venn diagram revealing the 119 specific bound proteins in the F1 fragment and 101 specific bound proteins in the F2 fragment. ( I ) RNAseq data of TCGA-ESCA item was downloaded from TCGA database ( https://portal.gdc.cancer.gov ), and DNMT1 mRNA expression in 174 cases of tumor samples and 11 cases of normal samples was analyzed. ( J ) IHC assay was employed to measure the expression of DNMT1 in five pairs of ESCC tumor tissues and adjacent normal tissues. ( K ) RT-qPCR demonstrating that in hypoxia-induced ESCC cells, decitabine (DCA) elevated RORA mRNA level, and DNMT1 upregulation decreased the mRNA level of RORA. ( L ) Western blotting demonstrating that in hypoxia-induced ESCC cells, decitabine (DCA) elevated RORA protein expression, and DNMT1 upregulation inhibited the protein level of RORA. ( M ) ChIP qPCR confirming the binding of DNMT1 and the RORA promoter in hypoxia-induced KYSE150 ESCC cells. ( N and O ) DNA pyrosequencing indicating the enhancement of DNMT1 in the promoter methylation level of RORA in hypoxia-induced KYSE150 ESCC cells. * P < 0.05, ** P < 0.01, *** P < 0.001

Article Snippet: For analysis of protein expression, we used primary antibodies from Proteintech (Wuhan, China) including rabbit anti-RORA polyclonal antibody (pA) (1:1,500, #10616-1-AP), rabbit anti-HIF1A polyclonal antibody (pA) (1:8,000, #20960-1-AP), rabbit anti-Snail pA (1:800, #13099-1-AP), rabbit anti-N-cadherin pA (anti-N-cad, 1:5,000, #22018-1-AP), rabbit anti-E-cadherin pA (anti-E-cad, 1:30,000, #20874-1-AP), rabbit anti-SLC2A3 pA (1:4000, #20403-1-AP), and mouse anti-β-actin monoclonal antibody (mAb) (1:10,000, #81115-1-RR).

Techniques: Methylation, DNA Methylation Assay, Expressing, Quantitative RT-PCR, Western Blot, ChIP-qPCR, Binding Assay

Journal: Journal of Translational Medicine

Article Title: DNMT1-driven methylation of RORA facilitates esophageal squamous cell carcinoma progression under hypoxia through SLC2A3

doi: 10.1186/s12967-024-05960-8

Figure Lengend Snippet: The downstream targets of RORA are screened by RNA-seq. ( A ) GO function annotation of the significantly down-regulated genes in RORA + hypoxia group versus vec + hypoxia group was performed. ( B ) The differentially expressed genes were shown by the volcano plot, and blue for down-regulated genes, red for up-regulated genes. ( C ) The mRNA expression levels of SLC2A3 and SLC2A14 in vec + hypoxia and RORA + hypoxia groups were determined by RT-qPCR. ( D ) Western blot assay was employed to detect the protein level of SLC2A3 in vec + hypoxia and RORA + hypoxia groups. ( E ) The binding motif of RORA and the binding sequence between RORA and SLC2A3 promoter region were predicted by JASPAR database. ( F ) Three ChIP-qPCR primers of SLC2A3 promoter were designed based on the three predicted binding sites, and ChIP-PCR was employed to verify the binding sites between RORA and SLC2A3 promoter. ( G ) Dual-luciferase reporter assay was conducted to verify the binding sites between RORA and SLC2A3 promoter. * P < 0.05, ** P < 0.01, *** P < 0.001, ns: non significant

Article Snippet: For analysis of protein expression, we used primary antibodies from Proteintech (Wuhan, China) including rabbit anti-RORA polyclonal antibody (pA) (1:1,500, #10616-1-AP), rabbit anti-HIF1A polyclonal antibody (pA) (1:8,000, #20960-1-AP), rabbit anti-Snail pA (1:800, #13099-1-AP), rabbit anti-N-cadherin pA (anti-N-cad, 1:5,000, #22018-1-AP), rabbit anti-E-cadherin pA (anti-E-cad, 1:30,000, #20874-1-AP), rabbit anti-SLC2A3 pA (1:4000, #20403-1-AP), and mouse anti-β-actin monoclonal antibody (mAb) (1:10,000, #81115-1-RR).

Techniques: RNA Sequencing, Expressing, Quantitative RT-PCR, Western Blot, Binding Assay, Sequencing, ChIP-qPCR, Luciferase, Reporter Assay

Journal: Journal of Translational Medicine

Article Title: DNMT1-driven methylation of RORA facilitates esophageal squamous cell carcinoma progression under hypoxia through SLC2A3

doi: 10.1186/s12967-024-05960-8

Figure Lengend Snippet: The anti-tumor activity of RORA on migration and invasion of hypoxia-induced ESCC cells is largely based on its target SLC2A3. ( A ) RT-qPCR was employed to assess the overexpression efficiency of SLC2A3 plasmid. ( B-F ) ESCC cells were transfected with vector, RORA, or RORA + SLC2A3 and treated with hypoxia. ( E ) Cell migration ability was evaluated by wound-healing assay. ( C ) Transwell assay was employed to assess cell invasion ability. ( D and E ) The abundance of cell motility-related indicators (MMP2 and MMP9) was determined by IF assay. ( F ) Western blotting was conducted to detect the expression of EMT-associated markers (E-cad, N-cad, and Snail) in hypoxia-induced ESCC cells. * P < 0.05, ** P < 0.01, *** P < 0.001

Article Snippet: For analysis of protein expression, we used primary antibodies from Proteintech (Wuhan, China) including rabbit anti-RORA polyclonal antibody (pA) (1:1,500, #10616-1-AP), rabbit anti-HIF1A polyclonal antibody (pA) (1:8,000, #20960-1-AP), rabbit anti-Snail pA (1:800, #13099-1-AP), rabbit anti-N-cadherin pA (anti-N-cad, 1:5,000, #22018-1-AP), rabbit anti-E-cadherin pA (anti-E-cad, 1:30,000, #20874-1-AP), rabbit anti-SLC2A3 pA (1:4000, #20403-1-AP), and mouse anti-β-actin monoclonal antibody (mAb) (1:10,000, #81115-1-RR).

Techniques: Activity Assay, Migration, Quantitative RT-PCR, Over Expression, Plasmid Preparation, Transfection, Wound Healing Assay, Transwell Assay, Western Blot, Expressing

Journal: Journal of Translational Medicine

Article Title: DNMT1-driven methylation of RORA facilitates esophageal squamous cell carcinoma progression under hypoxia through SLC2A3

doi: 10.1186/s12967-024-05960-8

Figure Lengend Snippet: RORA restrains the glycolysis of hypoxia-exposed ESCC cells largely by targeting SLC2A3. ( A-C ) ESCC cells were transfected with vector, RORA, or RORA + SLC2A3 and treated with hypoxia. Cell glycolysis was analyzed by measuring the uptake of glucose and the generation of lactic acid and ATP. * P < 0.05, ** P < 0.01, *** P < 0.001

Article Snippet: For analysis of protein expression, we used primary antibodies from Proteintech (Wuhan, China) including rabbit anti-RORA polyclonal antibody (pA) (1:1,500, #10616-1-AP), rabbit anti-HIF1A polyclonal antibody (pA) (1:8,000, #20960-1-AP), rabbit anti-Snail pA (1:800, #13099-1-AP), rabbit anti-N-cadherin pA (anti-N-cad, 1:5,000, #22018-1-AP), rabbit anti-E-cadherin pA (anti-E-cad, 1:30,000, #20874-1-AP), rabbit anti-SLC2A3 pA (1:4000, #20403-1-AP), and mouse anti-β-actin monoclonal antibody (mAb) (1:10,000, #81115-1-RR).

Techniques: Transfection, Plasmid Preparation

Journal: The European Journal of Neuroscience

Article Title: Transcriptional profiling aligned with in situ expression image analysis reveals mosaically expressed molecular markers for GABA neuron sub‐groups in the ventral tegmental area

doi: 10.1111/ejn.14534

Figure Lengend Snippet: Primary antibodies

Article Snippet: Anti‐RORA , Rabbit , Sigma (#Av45608) AB_1856399 , 1:100.

Techniques: Concentration Assay